China Approves World's First CAR-T Therapy for Solid Tumors
There’s a quiet but consequential shift happening in oncology — one that moves CAR-T therapy, until now largely confined to blood cancers, into the far larger arena of solid tumors. On June 22, China’s National Medical Products Administration (NMPA) approved satricabtagene autoleucel (brand name: Kailimei) through its priority review pathway, making it the first CAR-T product anywhere in the world to receive regulatory approval for a solid tumor indication.